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Purpose: To descirbe a series of patients in which Thyroid Associated Orbitopathy (TAO) occurred after 
periocular surgery.
Methods: A retrospective case review of patients who developed TAO in close temporal association with 
periocular surgical interventions and presented at the orbital clinic from 1997 to 2004. History of previous 
thyroid abnormality and the lack of TAO signs and symptoms before surgery were reviewed and analyzed.
Results: Nine patients that developed TAO in association with periocular surgery were identified. All were 
women with an average age of 59.3years. (range: 45-75 years). The patients divided into two groups. Group 
1 consisted of four patients who had previously been diagnosed with Graves򰡑 hyperthyroidism (GH). They 
ranged in age from 48 to 75 years (average: 58.8 years). The diagnosis of GH had been made an average 
of 50.5 months (range: 12-96 months) before presentation with TAO. Group 2 consisted of five patients who 
had no previous history of thyroid abnormality. They ranged in age from 45 to 74 years (average: 60.2 
years). No patients had any signs or symptoms of TAO before their recent presentation.
Conclusions: Periocular surgery may lead to local inflammatory events that may contribute to the instigation 
of TAO in predisposed individuals.  Korean Journal of Ophthalmology 20(2):82-86, 2006
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Thyroid associated orbitopathy (TAO) was described by 
Graves in 1835
1 and by Von Basedow in 1840.
2 TAO occurs 
in 25 to 75% of immune mediated dysthyroidism patients 
with variable severity.
3 
TAO is associated with a hyperthyroid state in 85% of 
cases.
3 In a smaller percentage of cases the orbitopathy may 
be associated with Hashimoto’s thyroiditis (5%) or a 
euthyroid state (10%).
3,4,5,6,7 TAO can predate a dysthyroid 
state in up to 20% of cases.
3 The immune dysregulation 
produces both orbitopathy as well as the dysthyroid state, 
although the temporal relationship between the two varies. 
The etiology of TAO is unknown but causative factors 
include genetic predisposition, infections with viruses and 
Yersinia, stress, and smoking when preceded by Graves’ 
hyperthyroidism. The view that TAO is an autoimmune 
process is suggested by the coexistence with other auto-
immune diseases such as Myasthenia Graves disease, 
systemic lupus erythematosus, and vitiligo.
4,5,6,7,8
We present a series of nine patients in whom periocular 
surgery is possibly related to the initial presentation of TAO.
Materials and Methods
A retrospective case review was performed to identify 
patients who developed TAO in temporal association with 
periocular surgery. Patients who presented from 1997 to 2004 
were analyzed. 
The diagnosis of TAO was made using clinical signs and 
symptoms. Patients were examined for proptosis, lid 
retraction and lid lag, extraocular motility abnormalities, and 
periocular swelling. A standard assessment including slit 
lamp examination and color vision testing was also per-
formed. Radiological investigations (MRI or CT) were used 
to confirm clinical impressions and define extraocular muscle 
and orbital fat involvement.
University Institutional Review Board (IRB) / Ethics Com-
mittee approval was obtained by authors.
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Type  of  surgery
(Group  Ⅰ)
Previous 
Hyperthyroidism 
without  TAO
(Group  Ⅱ)
No  History 
of  thyroid 
Disease
Botox  injections
Cataract  surgery
Injectable  fillers
LASIK
Facelift / blepharoplasty /
laser  resurfacing / forehead  lift
1
1
1
1
1
1
3
Table 1. Types  of  periocular  surgery
Nine patients were identified, all of which female, ranging 
in age from 45-75 years (average: 59.3 years). This represents 
an incidence of 1.6% in our clinic population. 
Nine patients were identified comprising two main groups.
Group 1 was comprised of four patients who had previously 
been diagnosed with Graves’ hyperthyroidism. They ranged 
in age from 48-75 years (average: 58.8 yrs). The diagnosis 
of Graves’ hyperthyroidism had been made 12 to 96 months 
(average: 50.5 months) prior to presenting with orbitopathy.
Group 2 was comprised of five patients who were not 
documented to have had any previous or concurrent thyroid 
abnormality. They ranged in age from 45-74 years (average: 
60.2 years). 
None of the patients had previously been diagnosed with 
TAO in relation to their Graves’ disease
The periocular procedures performed are summarized in 
Table 1.
1. Group 1: Patients with Previous Diagnosis of 
Thyroid Abnormality
Four patients had been diagnosed as having Graves’ 
hyperthyroidism before surgery. All of these patients had 
been stable with no signs of TAO for an average of over four 
years before periocular surgery.
Here we present two interesting cases in group 1. 
Patient 1
This 48-year-old patient developed Graves’ disease in June 
of 1994 at age 38. She was treated with Iodine 131 and 
rendered euthyroid upon replacement thyroxine treatment.
In November 1999 she underwent bilateral LASIK surgery 
to correct her myopia. Immediately after surgery she noted 
swelling in the left eye. In December 1999 it was noted that 
she had proptosis in both eyes and left upper lid retraction. 
A CT scan showed an enlargement of both inferior rectus 
muscles. TSH and T3 levels were slightly elevated but she 
was essentially euthyroid. She was observed until she was 
stable and, in June of 2003, underwent a bilateral fat decom-
pression for cosmesis, followed by left upper lid retraction 
repair. 
Patient 2
This 59-year-old patient was diagnosed with Grave’s 
hyperthyroidism at 24 years of age and was treated for 12 
months with methimazole, by which time her thyroid levels 
had normalized. She required no further treatment until 
September 2001 when, at the age of 56, she again developed 
Graves hyperthyroidism. After an initial six-months treatment 
period with methimazole, she was treated with Iodine 131 in 
April of 2002. Iodine 131 was subsequently replaced with 
thyroxine and the patient was considered euthyroid.
In September of 2002 she underwent Botox injections to 
her eyelids and brow. It was noted that she had marked 
swelling after the injections and, in the next one to two 
months, developed bilateral lid retraction. There was no sign 
of proptosis or diplopia. At the time of presentation, the TSH 
level was normal, T4 was slightly elevated, and anti- thyroid 
peroxidase antibody was positive.
She did not develop any further signs of TAO and in 
February of 2004 underwent bilateral lid retraction repair 
with good postoperative results.
2. Group 2: Patients with No Previous Thyroid 
Abnormality
Five patients did not have any history of dysthyroid state 
or TAO before their periocular surgery.
Two intresting cases in group 2 are presented here.
Patient 1
This 74-year-old patient underwent left cataract extraction 
with retrobulbar injection in October of 1999. Postopera-
tively, she noted swelling and two months later developed 
left upper lid retraction. She noted pain and burning in her 
eyes and developed vertical diplopia. Thyroid function tests 
showed normal T4 and T3 levels and a mild suppression of 
TSH with positive TSH receptor antibodies.
In April of 2000 she was noted to have mild bilateral 
proptosis that was more severe in the left eye, and left upper 
lid retraction. An MRI showed an enlarged left superior 
rectus muscle. Because of the atypical presentation she 
underwent biopsy of the enlarged muscle in October 2000, 
which showed inflammatory changes consistent with Graves’ 
hyperthyroidism. The diplopia slowly worsened and in June 
2001 a CT scan showed bilateral enlargement of all 
extraocular muscles, which was greater in the left eye. After 
spontaneous stabilization of the orbitopathy she underwent 
bilateral strabismus surgery in July 2001 and again in July 
2002 to treat her diplopia. 
She remained euthyroid until October 2003 when she 
developed clinical hyperthyroidism with grossly elevated T4 
and suppressed TSH. She began methimazole treatment for 
her Graves’ hyperthyroidism in December 2003.
Patient 2
This 71-year-old patient underwent cosmetic surgery 
consisting of facelift, bilateral upper lid blepharoplasty, and 
lower lid laser resurfacing in December 2002. She noted Korean  J  Ophthalmol  Vol.20,  No.2,  2006
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Patient Age Previous
Hyperthyroidism Type  of  Surgery Signs  of  TAO
Time  of  surgery
  to  orbitopathy 
(weeks)
Sex
Time  Graves
 t o  S u r g e r y  
(months)
Thyroid 
abnormality
1 59 Yes Botox  injection  to 
eyelids  and  brow
LR
LS
4F 1 2E u t h y r o i d
2 53 Yes 4  lid  blepharoplasty LR/LS/REM/P/D 4 F 96 Euthyroid
3 75 Yes Cataract/RBA LR/REM/P/D/ONC 4 F 29 Euthyroid
4 48 Yes LASIK LR/LS/P 4 F 65 Euthyroid
5 74 No Cataract/RBA LR/LS/D/P 6 F N/A Developed 
Graves’
6 71 No Facelift/4  lid  blepharoplasty/
Laser  resurfacing
P/REM/ONC 4 F N/A Developed 
Graves’
7 61 No Facelift/4  lid  blepharoplasty/
chin  implant
LR/REM/
ONC/D
4 F N/A Developed 
Graves’
8 48 No Bilateral  UL  blepharoplasty REM/D/P 8 F N/A Developed 
Graves’
9 45 No Hyaluronic  acid  injection LR/LS/D/P 4 F N/A Euthyroid 
Increased  Thyroid 
autoantibody
KEY:  LR-lid  retraction;  RBA-retrobulbar  anesthetic;  LS-lid  swelling;  REM-restricted  eye  movement;  P-proptosis;  D-diplopia;  ONC-optic 
nerve  compression
Table 2. Summary  of  patient  characteristics
significant postoperative edema that was worse on the left 
side, and in January 2003 prominence of her left eye. Upon 
examination she was noted to have left eye proptosis, brow 
swelling, and limited elevation of the left globe. An MRI 
showed enlargement of the left inferior rectus, as well as 
mild enlargement of the left superior and lateral rectus. 
In March 2003 she developed hyperthyroidism with 
elevated T4 and suppressed TSH, and began PTU therapy. 
In May 2003 she developed left compressive optic neuro-
pathy and was treated with prednisone and orbital radio-
therapy. The prednisone treatment was tapered to zero and 
by December 2003 her vision had stabilized.
We present a series of four patients among nine who 
developed TAO in temporal relationship to periocular 
surgery. There were five patients (Group 2) without a history 
of thyroid dysfunction prior to surgery. Four of these patients 
subsequently developed Graves’ hyperthyroidism (This 
occurred 2, 3, 11, and 48 months after TAO diagnosis) and 
the fifth tested positive for auto-antibodies. 
In each of these patients there was a temporal relationship 
between their surgery and the development of TAO. In all 
patients TAO developed within six weeks of the periocular 
surgery. 
All patients developed proptosis and upper lid retraction 
and four of the five had diplopia due to extraocular muscle 
enlargement. Two patients developed compressive optic 
neuropathy that required steroid and orbital radiotherapy. 
Two patients underwent orbital decompression for cosmesis 
after stabilization of the TAO. Four of the five patients 
required lid surgery, and three of five required extraocular 
muscle surgery.
Four patients had previous history of thyroid abnormality 
(Group 1). In all patients there was significant lid retraction, 
three of four developed diplopia, and one patient developed 
compressive optic neuropathy. 
A summary of the cases is presented in Table 2.
Discussion
We studied nine patients in whom surgery on or around 
the eye was temporally associated with the development of 
TAO, both in patients with previously stable Graves’ hyper-
thyroidism and in patients with no previous thyroid disease 
history. Before discussing this group of patients further it is 
important to note how they differ from previously described 
TAO patients. All patients were euthyroid at the time of 
TAO, which is uncommon with most patients developing 
TAO in the setting of systemic hyperthyroidism or more 
uncommonly, hypothyroidism.
3,9,10
Five patients (Group 2) had no previous thyroid 
abnormality. Four patients (Group 1) had been treated for 
Graves’ hyperthyroidism. While it may be argued that the 
development of TAO was part of the natural history of the 
disease, three of the four patients had stable Graves disease 
for at least 29 months before the surgical event. Bartley 
reported that the usual temporal relationship of hyper-
thyroidism and the development of TAO is 18 months in 
85% of patients.
3,9,10 Our observed time interval falls outside 
that expected between thyroid dysfunction and the develop-
ment of orbitopathy. In only 15% of cases does TAO develop S J  K i m ,  e t  a l .  T H Y R O I D  A S S O C I A T E D  O R B I T O P A T H Y  F O L L O W I N G  P E R I O C U LAR  SURGERY
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before or after this time period. One of the four patients had 
Botox injections 12 months after the diagnosis of Graves’ 
disease, and it could be argued that the development of TAO 
was merely coincidental to the treatment. Two patients with 
previous Graves’ hyperthyroidism developed TAO at least 
five years after their original diagnosis.
It is of note that all patients were women. The usual ratio 
of women to men when one considers TAO is around six to 
one.
9 The average age of the patients in this study was 59.3 
years, which corresponds to the second peak in the bimodal 
distribution of TAO seen in women.
9,11 
The pathogenesis of TAO has been a topic of controversy 
for many years. The instigation of the extrathyroidal mani-
festations of Graves’ disease and other dysthyroid states has 
yet to be explained. The original description by Graves and 
Von Basedow in the 1830s
1,2 included pretibial myxedema, 
hyperthyroidism, and Orbitopathy, and for years a common 
auto-antigen has been sought.
12 Initially extraocular muscle 
antigens 13 and the TSH receptor were considered likely 
auto-antigens.
14 These antigens are however not limited to the 
sites that manifest changes in Graves disease.
15 
More recently the central role of the unique orbital 
fibroblast has been implicated in TAO.
16,17 Studies have 
identified the role of the orbital fibroblast as a target of the 
T-cell mediated infiltration of the orbital connective tissues. 
Orbital and pretibial fibroblasts possess unique phenotypic 
behavior. Orbital fibroblasts in particular are neural crest 
derived
17 and express CD40 (a typical B-cell cell surface 
receptor) that can be activated by T-cell receptor (CD154) 
linkage to elicit inflammatory cytokines and bone marrow 
derived cell migration factors.
18,19 
Moreover, a subpopulation of orbital fibroblasts can 
undergo adipocyte differentiation in vitro when placed in 
appropriate culture media, and can be induced by 20 inflam-
matory cytokines to produce up to a 100-fold greater amount 
of glycosaminoglycan than normal fibroblasts.
21,22 These 
latter two properties explain the exaggerated, glycosamino-
glycan deposition and fat proliferation obseved in TAO 
patients.23 The effect on the orbits can be unilateral in as 
many as 10% of cases.
It is difficult to find any previous analysis of the type of 
patients examined in this study.
Some authors have suggested that trauma and pressure 
may play a central role in the sites of extrathyroidal mani-
festations of TAO.
24,25 Previous authors have described TAO 
as a cause of diplopia after cataract surgery.
26 These authors 
described 58 patients who developed unexpected diplopia 
after cataract surgery. It was found that eight of these patients 
had concurrent TAO. Three patients had been previously 
diagnosed with stable Graves’ hyperthyroidism, two subse-
quently developed dysthyroid changes, and three patients 
were euthyroid. In seven patients, retrobulbar anesthetic 
injection was used for the cataract surgery.
Previously, authors have postulated traumatic aggravation 
of subclinical TAO as the explanation for the symptoms. A 
single case report of TAO in a previously stable Graves’ 
hyperthyroidism patient
27 postulates a local pressure 
mechanism for the induction of TAO, and extrapolates this 
to suggest that local factors are the main determinant of the 
extrathyroidal manifestations of dysthyroid states. In this 
particular case, the patient had previously stable hyperthyroi-
dism and developed TAO after cataract extraction with 
retrobulbar anesthesia. It has also been suggested that Iodine 
131 treatment can exacerbate or incite TAO in the acute 
phase of Graves’ hyperthyroidism.
28
The role of localized trauma from periocular surgery may 
be central to TAO develpoment in the nine patients identified 
in this study.
It may be that, in the patients with a pre-existing 
dysthyroid state, the local trauma of the surgery led to 
inflammation in a pre-sensitized host that stimulated the 
development of TAO. In the subset of patients with no 
previous dysthyroid state (Group 2), other factors may also 
be involved. Surgery may lead to the development of TAO 
and Graves’ hyperthyroidism in predisposed patients. These 
immunologically susceptible people may be impacted by 
local mechanisms that prime site-specific responses.
It is of note that smoking imposes a seven-fold increased 
risk for the development of TAO in people who develop 
thyroid dysfunction. The mechanism for this is unknown, but 
it may be related to microvascular ischemia that causes 
anoxic responses in all tissues, but the site specificity is 
granted via particular cell types in the orbit. Local trauma 
may lead to local inflammatory pathways sensitizing orbit- 
specific cells and priming the immune system to various 
site-specific antigens including the orbit and thyroid gland. 
It is possible that the five patients (Group 2) who had no 
history of dysthyroid state may have had subclinical Graves’ 
hyperthyroidism in which the progression to TAO was simply 
coincidental with the surgery they underwent. However, no 
constant symptom during the detailed history review was 
found to suggest this.
It is important to quickly identify this subgroup of patients 
as the manifestations of TAO are more severe in middle aged 
or older patients,
3 and certainly three patients in this study 
required systemic treatment, radiotherapy, and eventual 
surgery to alleviate compressive neuropathy due to their 
TAO.
Although it is difficult to generalize a condition with such 
protean manifestations, it may be reasonable to screen 
patients on a history basis for any immunological mediated 
thyroid disease.
We do not necessarily advocate thyroid function tests for 
all preoperative patients, but in many centers they are 
routinely done as part of the preoperative workup. There may 
be a role for preoperative baseline blood work to detect the 
use of systemic steroids before periocular surgery in a patient 
that gives a history of a previous immunological mediated 
dysthyroid state.
Shortcomings of this study are the lack of a control group Korean  J  Ophthalmol  Vol.20,  No.2,  2006
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and the small number of participants.
Additional case-control studies will be needed to identify 
the cause-and-effect relationship between TAO and periocular 
surgery. 
Conclusion
In this paper we present nine patients who developed TAO 
of varying severity after cataract surgery or cosmetic surgery 
around the orbit. This may be related to the local inflam-
matory process stimulating exaggerated autoimmune responses 
in predisposed individuals. Furthermore, it may be important 
to counsel patients with pre-existing dysthyroid states 
undergoing surgery about the possibility of exacerbating their 
condition.
Lastly, in cosmetic surgery patients, any prolonged 
recovery or development of diplopia or lid retraction may 
prompt an investigation for TAO.
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